The U.S. FDA is unable to pursue plans to increase inspections or collaborate on public health strategies and regulatory practices in China because of difficulty acquiring visas from the country, Ed Silverman writes. The delay is a blow to the agency's push to enhance the pharmaceutical supply chain's safety, Silverman writes. "We believe that timely issuance of visas for FDA staff will be beneficial to both the U.S. and China, and that it's in China's best interest to issue these visas, and move on to our next stage of collaboration," an FDA spokesman said.

Full Story:

Related Summaries